Preoperative use of SGLT2 inhibitors among patients with type 2 diabetes undergoing emergency surgery was not associated with ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...

Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

Researchers have found in a new study that SGLT2 inhibitors may have disease-modifying effects in nonsevere aortic stenosis ...

A new study, authored by KBH Professor Jan Inge Henter and published in the New England Journal of Medicine, has investigated ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...